Brownstone Nicholas D, Hong Julie, Mosca Megan, Hadeler Edward, Liao Wilson, Bhutani Tina, Koo John
University of California, San Francisco, Department of Dermatology, Psoriasis and Skin Treatment Center, San Francisco, CA, USA.
Biologics. 2021 Feb 16;15:39-51. doi: 10.2147/BTT.S252578. eCollection 2021.
The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care.
在过去二十年中，生物制剂的出现极大地改善了银屑病和银屑病关节炎的治疗。鉴于目前有11种经美国食品药品监督管理局（FDA）批准的用于治疗银屑病的生物制剂可供选择，且还有更多正在研发中，治疗手段已得到极大增强。然而，有如此多的可用选择这一事实也给医疗服务提供者带来了困惑。因此，本手稿特意聚焦于每种经FDA批准的用于银屑病的生物制剂（包括正在研发的制剂）最具临床实用性的事实（如疗效和安全性数据）。此外，在临床相关事实中，本手稿特意强调每种制剂的独特优缺点，以便医疗服务提供者更容易选择众多选项中哪一种最适合手头的特定患者。本手稿的目标是帮助忙碌的皮肤科执业医生更熟练地使用这些制剂，最终目的是改善患者护理。
